GSK moved a step closer to securing approval to sell an over-the-counter version of Roche's weight-loss drug Xenical in the USA late Friday, after the FDA gave conditional approval for the product.
GSK is hoping to sell an OTC version of Xenical (orlistat) under the "Alli" brandname, and said the notification from the FDA that its application is 'approvable' puts it on track for a launch later this year, once certain questions raised by the agency have been answered.
Like Sanofi Aventis did with their dieting hope Acomplia , GSK did not disclose the conditions that must be met before a green light will be given.
Source: PharmaTimes
No comments:
Post a Comment